Dr. Ningxi Zhu

1718 Braeswood Dr, Corpus Christi TX 78412
361-992-8500

EDUCATION

1998- 2001: Zhejiang University, Hangzhou, China
(Ph.D. in Hematology/Oncology)

1987- 1990: Shanghai Medical University, Shanghai, China
(Master Degree of Medical Science)

1982- 1987: Wenzhou Medical University, Wenzhou, China (M.D.)

TRAINING

2011- 2013: Creighton University (Allergy/Immunology Fellowship)

2008- 2001: Driscoll Children's Hospital (Pediatric Residency)

1990- 1993: Zhejiang Provincial Hospital of Hangzhou, China
(Hematology Fellowship)

1987- 1990: Shanghai Medical University, China
(International Medicine Residency)

BOARD CERTIFICATION

2013: American Board of Allergy and Immunology

2011: American Board of Pediatrics

2006- 2008: Recipient of Postdoctoral grant
(Hope Street Kids Foundation) for a novel study of neuroblastoma therapy

PROFESSIONAL SOCIETIES

AAAAI
ACAAI
Texas Medical Association

PROFESSIONAL EXPERIENCE AND APPOINTMENTS

July 2013- Present: Driscoll Children's Hospital (Teaching Attending of Allergy and Immunology)

July 2013- Present: The Allergy and Asthma Center of Corpus Christi (Practicing Allergist and Clinical Immunologist)

2002- 2008: Emory University Children's Cancer Center (Postdoctoral Fellow)

1994- 2002: Zhejiang Provincial Hospital at Hangzhou, China (Attending physician, associate professor in Hematology)

SPECIAL INTERESTS

- Treatment of Nasal Allergies
- Treatment of Skin Allergies
- Treatment of Insect Allergies
- Treatment of Food Allergies
- Treatment of Refractory Asthma
- Treatment of eczema
- Treatment of hives
- AERD and Aspirin Desensitization
- Pediatric Primary Immunodeficiency Disorders
- Hereditary Angioedema
- Providing Quality Care and Relief to Local Community
- ABSTRACTS AND PUBLICATIONS (Allergy and Immunology)
- The effects of cigarette smoking on the expression of RGS2 gene and airway
- hypersensitivity (Oral presentation, 2013, AAAAI meeting)
- Type III hereditary angioedema-case reports (Poster presentation, 2013 ACAAI meeting)

PUBLICATIONS (others, representative)

1. Gu L, Zhu N, Zhang H, Durden DL, Feng Y, and Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell. 2009 May; 15(5): 367-75

2. Zhu N, Gu L, and Zhou M. Inhibition of the Akt/survivin pathway synergizes the antileukemic effect of Nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther. 2008 May; 7(5): 1001-9

3. Fang J, Gu L, Zhu N, Tang H, Alvarado CS, and Zhou M. Tissue factor/FVIIa activities BCL-2 and prevents doxorubicin - induced apoptosis in neuroblastoma cells. BMC Cancer. 2008 Mar; 6(8): 69

4. Gu L, Zhu N, Findley HW, and Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of

apoptosis in pediatric lymphoblastic cells with wild-type p53 and overexpression of MDM2. Leukemia. 2008 April; 22(4): 730-9

5. Gu L, Chiang KY, Zhu N, Findley HW and Zhou M. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol. 2007; 35(6): 957-66

6. Zhu N, Gu L, Findley HW Chen C, Dong JT, Yang L and Zhou M. KLF5 interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J. Biol. Chem. 2006; 281(21): 14711-14718

7. Gu L, Findley HW, Zhu N and Zhou M. Endogenous TNFalpha mediates cell survival and chemotherapy resistance by activating the P13K/Akt pathway in acute lymphoblastic leukemia cells. Leukemia. 2006; 20(5): 900-4

8. Zhu N, Gu L, Findley HW, Zhou M. Transcriptional repression of the eukaryotic factor 4E9elF4E) gene by wildtype p53 in leukemia. Biochem Biophys Res Commun. 2005; 335(4): 1272-9

9. Zhu N, Gu L, Findley HW, Woods WG, Zhou M. Identification and characterization of the IKKalpha promoter: Positive and negative regulation by Ets-I and p53, respectively. J Biol Chem. 2004; 279(50): 52141-9

10. Zhu N, Gu L, Findley HW, Li F, Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene. 2004 23:7545-7551

11. Zhou M, Gu L, Zhu N, Woods WG, Findley HW, Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm p53. Oncogene. 2003 Nov 6;22(50): 8137-44